BridgeBio Pharma BBIO Reportable Segment — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:ProfitLoss.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's reportable segment — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's reportable segment — net loss?
- BridgeBio Pharma (BBIO) reported reportable segment — net loss of -$166.56M in Q1 2026.
- How has BridgeBio Pharma's reportable segment — net loss changed year-over-year?
- BridgeBio Pharma's reportable segment — net loss increased by 1.8% year-over-year, from -$169.61M to -$166.56M.
- What does reportable segment — net loss mean?
- The total amount of money lost by the business segment after accounting for all costs and expenses.
- How do you interpret reportable segment — net loss?
- A narrowing loss indicates improved efficiency or revenue growth, while a widening loss suggests increasing costs or declining performance.
- How does reportable segment — net loss compare across companies?
- Common for pre-commercial or growth-stage biotech companies heavily investing in clinical pipelines.